Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE  Response to consultation
DATE  2019-05-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
CANNABIS FOR MEDICAL PURPOSES

Policy Document

LAST REVIEWED: 2019-03-03
DATE: 2010-12-04
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

The Canadian Medical Association (CMA) has always recognized the unique requirements of those individuals suffering from terminal illnesses or chronic disease for which conventional therapies have not been effective and for whom conventional benefits may be limited. Therefore, the CMA is not in a position to support the widespread, long-term use of cannabis for medical purposes, and for this reason will not actively encourage physicians to prescribe the drug.

The Canadian Medical Association is in favour of regulations that require the following:

1. Legitimacy: The status of cannabis for medical purposes must be made legitimate. The CMA recommends that governments take steps to ensure the accessibility, quality, and affordability of cannabis for medical purposes through the creation of a regulatory body that is independent from the pharmaceutical industry.

2. Access: Access to cannabis for medical purposes should be facilitated for all patients by ensuring that healthcare providers have the necessary training and resources to provide appropriate care.

3. Research: The CMA encourages further research into the risks and benefits of cannabis for medical purposes. This includes evaluating the efficacy of cannabis products, understanding the interactions between cannabis and other medications, and ensuring that research is conducted in a manner that respects ethical considerations.

The CMA makes the following recommendations:

1. The CMA recommends that the government consider the establishment of a regulatory body that is independent from the pharmaceutical industry to ensure the accessibility, quality, and affordability of cannabis for medical purposes.

2. The CMA encourages healthcare providers to be educated about the risks and benefits of cannabis for medical purposes, and to develop individualized treatment plans for patients.

3. The CMA supports ongoing research into the risks and benefits of cannabis for medical purposes, including evaluating the efficacy of cannabis products and understanding the interactions between cannabis and other medications.
Medication use and seniors (Update 2017)

https://policybase.cma.ca/link/policy10151

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2011-05-28

REPLACES
Medication use and seniors

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2012-12-08

TOPICS
Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE  
Response to consultation

DATE  
2019-02-20

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents